Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.

摘要: BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates docetaxel in various strata of recurrent solid tumors childhood assess toxicity a group patients who were assigned receive it. METHODS Docetaxel given at dose 125 mg/m2 once every 21 days as 1-hour intravenous infusion for maximum 12 courses. From January 1997 November 2001, 109 male 68 female (total, 177 patients) enrolled, 173 eligible. median patient age entry 13 years (range, 1-27 yrs). One hundred sixty evaluable response. RESULTS There no deaths attributable drug. Hematologic common during therapy. Dermatologic, neurologic, pulmonary, infectious side effects well edema significant. each had acute myeloid leukemia, lymphoid high-grade glioma reported secondary malignancies. with osteosarcoma 1 rhabdomyosarcoma achieved complete response. Partial responses observed Ewing sarcoma (3 patients), (1 patient), squamous cell carcinoma medulloblastoma patient). Seventeen stable disease. 1-year 5-year overall survival the 160 24% (standard error = 4%) 6% 2%), respectively. CONCLUSIONS Docetaxel demonstrated but found be ineffective treating other types that studied. Cancer 2006. © 2006 American Society.